Marinus Pharmaceuticals, Inc. (MRNS)

USD 0.24

(-1.38%)

Market Cap (In USD)

13.44 Million

Revenue (In USD)

30.98 Million

Net Income (In USD)

-141.4 Million

Avg. Volume

685.88 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.23-11.26
PE
-
EPS
-
Beta Value
1.262
ISIN
US56854Q2003
CUSIP
56854Q200
CIK
1267813
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Scott N. Braunstein M.D.
Employee Count
-
Website
https://marinuspharma.com
Ipo Date
2014-07-31
Details
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.